Vol 12, Supp. B (2021)
Case report
Published online: 2021-06-11

open access

Page views 235
Article views/downloads 292
Get Citation

Connect on Social Media

Connect on Social Media

Variable clinical course of immune thrombocytopenia

Joanna Zdziarska1


The clinical course of immune thrombocytopenia (ITP) is variable and includes both spontaneous remissions and aggravation phases. Treatment toxicity can sometimes overweight its benefits, especially in case of chronic corticosteroid therapy or immunosuppression. Introduction of thrombopoietin receptor analogues is a breakthrough in ITP treatment. I present a case of a 66-old-year patient with refractory ITP and unpredictable platelet count fluctuations, who was treated with eltrombopag.

Article available in PDF format

View PDF (Polish) Download PDF file


  1. Neunert C, Terrell D, Arnold D, et al. American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv. 2019; 3(23): 3829–3866.
  2. Provan D, Arnold DM, Bussel JB, et al. Updated international consensus report on the investigation and management of primary immune thrombocytopenia. Blood Adv. 2019; 3(22): 3780–3817.
  3. Zawilska K, Podolak-Dawidziak M, Chojnowski K, et al. Polskie zalecenia postępowania w pierwotnej małopłytkowości immunologicznej, opracowane prze Grupę ds. Hemostazy Polskiego Towarzystwa Transfuzjologów i Hematologów. PAMW. 2010; 120(Suppl).
  4. Matzdorff A, Neufeld EJ, Roganovic J. To treat or not to treat — from guidelines to individualized patient management. Semin Hematol. 2013; 50(Suppl 1): S12–S17.

Hematology in Clinical Practice